Researchers complete myotonic dystrophy treatment research

June 27, 2018, Asociacion RUVID
Translational Genomics group. Credit: Asociación RUVID

Researchers at the Translational Genomics laboratory of Valencia University and the INCLIVA health research institute have just discovered a new approach for the treatment of myotonic dystrophy, a rare and incurable neuromuscular disease which does not have specific treatment. Their work has been published in Nature Communications.

Their research has discovered molecules that are able to increase the expression of MBNL proteins, which are crucial for the , and that way prevent many of the alterations present in the murine and cellular models of the disease.

The uncovered molecules are known as antagomiRs. An antagomiR is a small oligonucleotide which has been noticeably modified to improve its pharmaceutical characteristics. It is added to specific regulatory RNA, in this case miR-23b and miR-218, which naturally suppress the expression of MBNL proteins. By degrading the suppressors, they increase endogenous expression, which is a therapeutic target for the disease. Oligonucleotides are a new type of innovative medicines which, according to Beatriz Llamusi, co-author of the project, "are quickly reaching clinical practice and could provide medium-term solutions for numerous diseases which are intractable today."

Myotonic dystrophy originates due to expansions of the CTG triplet of the DMPK gene which, through a well documented process, abduct MBNL proteins and prevent them from carrying out their normal functions within the cell. Estefanía Cerro Herreros, first signer of the article, graphically describes this process: "It is as if we gathered all our teachers in a park instead of in a classroom: we would paralyse education." She adds that "the treatment we have discovered consists of increasing the endogenous expression of said genes. As if, following the previous example, we hired more teachers."

A crucial aspect of the research is the team's interest on collaborating with the pharmaceutical industry to transform these discoveries into real medicine. Rubén Artero, head of the research, believes it is necessary to create an environment around research centres "which favours the continuity of scientific discoveries until they develop into solutions that are requested by society." In this sense, the Translational Genomics group of Valencia University has previous experience with public-private collaborations focused on these developments and, in this specific case, is negotiating the creation of a spin-off company to progress in the development of these composites as potential therapies for . The research team recently organised the first Spanish convention on the use of oligonucleotides in human therapies (SMOT1) with broad participation of companies in the sector.

Explore further: Recent findings hold new implications for the pathogenesis of myotonic dystrophy

Related Stories

Recent findings hold new implications for the pathogenesis of myotonic dystrophy

September 12, 2012
An important breakthrough could help in the fight against myotonic dystrophy. The discovery, recently published in the prestigious scientific journal Cell, results from an international collaboration between researchers at ...

There is more going on in myotonic dystrophy type 1 than just alternative splicing

June 26, 2018
Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy that affects multiple organ systems. People with this condition develop progressive muscle wasting and weakness in their lower legs, hands, ...

Antisense oligonucleotides make sense in myotonic dystrophy

February 27, 2012
Antisense oligonucleotides – short segments of genetic material designed to target specific areas of a gene or chromosome – that activated an enzyme to "chew up" toxic RNA (ribonucleic acid) could point the way ...

Researchers reveal abnormal myokine signaling in congenital myotonic dystrophy

December 12, 2017
Myotonic dystrophy (DM) is the most common form of genetic muscular dystrophy that begins in adulthood. DM is characterized by progressive muscle wasting and weakness. People with this disorder often have prolonged muscle ...

Drug delivery strategy eliminates myotonia symptoms in mice with myotonic dystrophy

February 22, 2013
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease. ...

Recommended for you

Gene mutation found to cause macrocephaly and intellectual deficits

November 13, 2018
The absence of one copy of a single gene in the brain causes a rare, as-yet-unnamed neurological disorder, according to new research that builds on decades of work by a University at Buffalo biochemist and his colleagues.

Mutations, CRISPR, and the biology behind movement disorders

November 12, 2018
Scientists at the RIKEN Center for Brain Science (CBS) in Japan have discovered how mutations related to a group of movement disorders produce their effects. Published in Proceedings of the National Academy of Sciences, the ...

Decrease in specific gene 'silencing' molecules linked with pediatric brain tumors

November 12, 2018
Experimenting with lab-grown brain cancer cells, Johns Hopkins Medicine researchers have added to evidence that a shortage of specific tiny molecules that silence certain genes is linked to the development and growth of pediatric ...

Recessive genes explain only small fraction of undiagnosed developmental disorders

November 8, 2018
The Deciphering Developmental Disorders study has discovered that only a small fraction of rare, undiagnosed developmental disorders in the British Isles are caused by recessive genes. The study by researchers from the Wellcome ...

A look at how colds and chronic disease affect DNA expression

November 8, 2018
We're all born with a DNA sequence that encodes (in the form of genes) the very traits that make us, us—eye color, height, and even personality. We think of those genes as unchanging, but in reality, the way they are expressed, ...

Mutant protein tackles DNA guardian to promote cancer development

November 7, 2018
Melbourne scientists have discovered how tumour development is driven by mutations in the most important gene in preventing cancer, p53.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.